CANCER AND LEUKEMIA GROUP B

UMCC的科学和临床研究不断发展， 与CALGB的关系 UMCC教师参加CALGB科学 和行政委员会。 UMCC教师设计，行为和椅子 许多组研究并将大量患者（pts）输入CALGB 问题研究 我们的应计费用比2008年增长了40%以上。 过去四年。 UMCC教师坐在核心委员会和主持 急性白血病 UMCC赞助MCD CCOP，巴尔的摩VA医疗 中心（BVAMC），参与的当地医生和Vince Lombardi 癌症中心（VLCC）。 继续开展这些活动的资金将使 进一步增加UMCC的科学和行政参与 及其在集团内的附属公司。 UMCC I期研究（每年2 - 4项） 经常演变成组II期研究。 UMCC试点研究（通常 与其他CALGB机构进行）形成了概念基础 用于白血病、乳腺癌和肺癌的群体研究。 UMCC 是最大的白血病累积机构之一， 最大的累积机构。 我们的基础科学实验室 研究急性白血病，细胞，动物和临床药理学， 细胞和分子生物学以及基础科学实验室 VLCC的发展，形成了重要的相关科学资源， 组 UMCC及其合作机构（BVAMC，MCD， 参与医生和VLCC）建议进一步增加我们的收益， 每年有300人参加CALGB研究。 参与CALGB研究 将使UMCC及其附属医生有更多的治疗选择 为该小组正在研究的疾病患者提供服务。 最近增加 从UMCC到CALGB的三名外科医生将进一步增加主要的 成员机构应计费用。 UMCC和VLCC的辅助研究 白血病、小细胞肺癌、乳腺癌和 淋巴瘤对相关科学具有特别重要的意义。 这 赠款将使UMCC继续其高效的科学和 行政参与小组，并将继续允许我们 在大巴尔的摩/华盛顿地区建立科学基地。 这笔赠款还将允许继续优秀的飞行员 协议，并将允许UMCC监控和收集数据， 对UMCC和CALGB产生互惠互利。

The UMCC has had continuing growth of its scientific and clinical relationships with CALGB. UMCC faculty participate in CALGB scientific and administrative committees. UMCC faculty design, conduct and chair many group studies and enter large numbers of patients (pts) onto CALGB studies. There has been greater than 40% growth in our accrual over the last 4 years. UMCC faculty sit on the core committees and chair the Acute Leukemia. UMCC sponsors the MCD CCOP, the Baltimore VA Medical Center (BVAMC), participating local physicians and the Vince Lombardi Cancer Center (VLCC). Funding to continue these activities will allow further growth in the scientific and administrative participation of UMCC and its affiliates in the group. UMCC phase I studies (2 - 4 per year) frequently evolve into group phase II studies. UMCC pilot studies (often performed with other CALGB institutions) have formed the conceptual basis for groupwide studies in leukemia, breast cancer and lung cancer. UMCC is one of the largest accruing institutions for leukemia and one of the largest accruing institutions overall. Our basic science laboratories studying acute leukemia, cellular, animal and clinical pharmacology, and cellular and molecular biology as well as the basic science laboratories of the VLCC, form an important correlative science resource for the group. UMCC and its collaborating institutions (BVAMC, MCD, participating physicians, and VLCC) propose to further our accrual beyond 300 entries per year onto CALGB studies. Participation in CALGB studies will allow UMCC and its affiliated physicians greater treatment options for patients with diseases under study by the group. The recent addition of three surgeons from UMCC to CALGB will further increment the main member institutional accrual. Ancillary studies in UMCC and VLCC laboratories in leukemia, small cell lung cancer, breast cancer and lymphoma will be of particular importance for correlative science. This grant will allow UMCC to continue its highly effective scientific and administrative participation in the group and will continue to allow us to develop a scientific base in the greater Baltimore/Washington area. This grant will also allow for the continuation of meritorious pilot protocols and will allow UMCC to monitor and collect data which will produce mutual benefit to the UMCC and CALGB.